Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress

NCT: NCT07027657 · COMPLETED

NCT IDNCT07027657
StatusCOMPLETED
Start Date2025-05-02
Completion2025-11-11

Brief Summary

The goal of this clinical trial is to evaluate whether the treatment with BTL-699-2 device is able to improve sleep quality and reduce stress in adults above the age of 22 years. The main questions it aims to answer are: Does the treatment with BTL-699-2 device improve sleep quality? Does the treatment with BTL-699-2 device reduce stress? Participants will be asked to: * Undergo six treatments * Complete the Pittsburgh Sleep Quality Index * Complete the Perceived Stress Scale Questionnaire * Complete the Sleep and Stress Assessment Questionnaire * Complete the Therapy Comfort and Subject Satisfaction Questionnaire

Frequently Asked Questions

What is EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress?

EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress is a clinical trial registered under NCT07027657. Current status: COMPLETED.

What is the status of NCT07027657?

The current status of NCT07027657 (EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress) is: COMPLETED.

When did EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress start?

EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress started on 2025-05-02.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.